Can l-carnitine reduce post-COVID-19 fatigue?
Roya Vaziri-Harami, Parisa Delkash
Abstract
A significant number of patients infected with the new coronavirus suffer from chronic fatigue syndrome after COVID-19, and their symptoms may persist for months after the infection. Nevertheless, no particular treatment for post-disease fatigue has been found. At the same time, many clinical trials have shown the effectiveness of l-carnitine in relieving fatigue caused by the treatment of diseases such as cancer, MS, and many other diseases. Therefore, it can be considered as a potential option to eliminate the effects of fatigue caused by COVID-19, and its consumption is recommended in future clinical trials to evaluate its effectiveness and safety.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Clinical trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Chronic fatigue syndrome2019-20 coronavirus outbreakCarnitineDiseaseIntensive care medicineChronic fatigueInternal medicinePathologyOutbreakInfectious disease (medical specialty)Long-Term Effects of COVID-19Fibromyalgia and Chronic Fatigue Syndrome ResearchCOVID-19 and Mental Health